The outlook for ablation and cardiac rhythm management technologies is looking up, according to Leerink Partners analyst Danielle Antalffy, writing after reviewing the latest offerings from medical device companies at the annual Heart Rhythm Society meeting in Boston recently.
September 29, 2014 by Alexander Soule
Acutus Medical said it secured $26.2 million in new funding for the cardiac mapping technology it’s developing to image and map atrial fibrillation hotspots.
European regulators approved Acutus Medical’s flagship ‘Katheter’ device, a diagnostic catheter for real-time 3D imaging and mapping of the heart.
The Katheter is just a part of Acutus Medical’s larger stand-alone system, the company said. The device contains 48 ultrasound crystals and electrodes that capture both the geometry of the heart and its electrical activity.
San Diego medical device startup Acutus Medical closed its Series B funding round with $28 million raised from a handful of investors in support of the company’s minimally invasive heart mapping technology.
Acutus Medical, fresh off a successful first-in-human trial of its heart-mapping technology, raised $21.6 million of a hoped-for $30.6 million Series B round, founder, president & CEO Randy Werneth told MassDevice.com today.
Edwards Lifesciences Corp. (NYSE:EW) landed a new four-year $500 million credit facility after canceling a prior one a couple months early.
The old facility was a five-year deal, also for $500 million, that was scheduled to mature September 29, 2011.